Value Line (NASDAQ: VALU) has initiated coverage of Medidata Solutions in its flagship product, The Value Line Investment Survey
. Beginning Monday, September 10th, Value Line’s analysts are evaluating the performance and business fundamentals of this stock. The following is based on information in the company’s SEC filings.
Medidata Solutions provides cloud-based clinical development solutions that help organizations with the clinical trial process. Its customers are typically pharmaceutical, biotechnology, and medical device developers and manufacturers. The company employs almost 700 individuals and is headquartered in New York, NY. Its market capitalization is approximately $950 million.
Read a more detailed overview at
For more information about the particular investment merits of Medidata Solutions, subscribers can visit
to access our full research report in The Value Line Investment Survey.
Value Line, Inc. is a leading New York-based provider of investment research. The Value Line Investment Survey is one of the most widely used sources of independent equities investment research. Value Line also produces a range of proprietary investment research in both print and digital formats including our acclaimed research in the areas of Mutual Funds, Options, Convertible securities and ETFs. Value Line’s trusted research also enables the Company to provide specialized products such as Value Line Select
, The Value Line Special Situations Service
, Value Line Dividend Select and proprietary data and ranking systems, distributed under copyright data agreements for fees. Value Line
products are available at
or by calling a representative at 1-800-VALUELINE. Institutional-level services are available at
Value Line announces new coverage initiations regularly. Look for our press releases. Follow
on Twitter and at